FOLH1 and prostate cancer: In prostate cancer, stereotactic body radiotherapy and PSMA-targeted radioligand therapy (e.g., 177Lu-PSMA-617) are prime candidates for eliciting ICD, potentially amplifying the efficacy of checkpoint blockade or vaccine-based strategies [118].